Pain Management Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

The Pain Management Market is Segmented by Mode of Pain Management (Drugs and Devices), Application (Neuropathic Pain, Cancer Pain, Facial Pain and Migraine, Musculoskeletal Pain, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.


Market Snapshot

Pain Management Market  Summary
Study Period: 2022-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.39 %
Pain Management Market  Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global pain management market was valued at USD 79,448.93 million in 2021, and it is projected to be worth USD 120,781.07 million, registering a CAGR of 7.39% during the forecast period of 2022-2027.

The COVID-19 pandemic has impacted the healthcare systems across the world. The health agencies are engaged in containing coronavirus transmission through lockdown norms and have deferred most of the elective and non-urgent surgeries globally. As per the research article published in the Indian Journal of Anaesthesia 2020, COVID-19 negatively impacted pain clinics, including interventional pain management procedures. The Indian Society of Anaesthesiologists also published guidelines on anesthesia and intensive care practices. However, these guidelines did not have information about chronic pain patients' management aspects until April 2020. Also, the research study published in the Journal of Pain Medicine 2020 suggested that the use of epidural nonsteroid injections for radicular pain can be considered in patients who were already immunosuppressed and at high risk of SARS-CoV-2 infection and complications. However, the possibility of treatment failure requiring a subsequent procedure must be weighed against the risk of infection. The non-urgent nature of most chronic pain management adversely affected the psychological health of patients during the pandemic. During the COVID-19 pandemic, patients with acute pain were untreated as they avoided hospital visits for fear of infection. On the other hand, the social isolation during the pandemic led to passive coping strategies, leading to depression and anxiety. Thus, the COVID-19 pandemic had a significant impact on the pain management market globally.

The growth of the pain management market is majorly due to the well-established business of painkiller medications as the first line of treatment. However, in recent years, the increasing reliance on their prolonged use and a greater understanding of their side effects have led to the growing use of device-based pain management therapies. Post-surgical pain is one of the primary focuses of hospitals. The cost of monitoring and the treatment of adverse effects creates a significant demand for pain management drugs and devices.

The current market is gradually adopting more non-opioid medications to suppress the addiction to opioids and certain well-established painkillers in the market. There are several non-opioid drugs with mechanisms of action, which are currently in the early and late stages of development. The regulatory authorities in multiple countries are shifting to alternative approaches, thus fast-tracking those drugs to market approval. The shift is expected to be gradual. Thus, pain management has desirable growth prospects during the forecast period.

The increasing aging population globally is expected to drive the market's growth, as the prevalence of chronic pain is relatively high among the geriatric population and is considered an independent risk factor for mortality. The increasing product launches are also expected to drive the market. For instance, in March 2020, Biotricity Inc. launched an innovative pain management product with CPM Centres for Pain Management, a subsidiary of NeuPath Health. Thus, due to such factors, the pain management market is expected to grow significantly over the forecast period. However high procedural and purchase costs of pain management devices can restrain the market growth.

Scope of the Report

As per the scope of the report, pain is defined as an unpleasant sensation in the body due to ongoing or impending tissue damage. Pain management includes therapies, drugs, and devices that help alleviate the pain. The pain management market is segmented by mode of pain management (drugs and devices), application (neuropathic pain, cancer pain, facial pain and migraine, musculoskeletal pain, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value in USD million for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally

Mode of Pain Management
Non-narcotic Analgesics
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Other Non-narcotic Analgesics
Neurostimulation Devices
Transcutaneous Electrical Nerve Stimulation (TENS) Devices
Brain and Spinal Cord Stimulation (SCS) Devices
Analgesic Infusion Pumps
Intrathecal Infusion Pumps
External Infusion Pumps
Neuropathic Pain
Cancer Pain
Facial Pain and Migraine
Musculoskeletal Pain
Other Applications
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Cancer Pain Segment is Expected to Exhibit Significant Growth Rate During the Forecast Period

Pain during cancer occurs the most when a tumor presses on the bones, nerves, or organs. The pain may vary according to the affected location. Chemotherapy, radiotherapy, and surgery can also cause pain. Pain caused by cancer can be treated, and many medicines are used for pain management in cancer patients. Some drugs are general pain relievers, while others target specific types of pain that may require a prescription.

As per the research article published in the JCO Global Oncology 2020, during the COVID-19 outbreak, nearly 88% of the cancer care centers faced challenges in delivering usual cancer care for many reasons, including preventive measures, lack of personal protective equipment, and staff shortage. These challenges were more pronounced in low-income countries. Therefore, the pandemic has hindered a lot of cancer therapies, which may indirectly impact the cancer pain segment.

The global incidence of cancer is high. As per the GLOBOCAN 2020 report, the incidence of new cancer cases was 19,292,789 globally with a male population of 10,065,305 and 92,274,84 with a female population. Thus, the high incidence of cancer worldwide may increase the demand for cancer therapies, which in turn is likely to boost the demand for cancer pain management drugs and devices and boost the market’s growth.

Pain Management Market: Estimated Number of New Cases of Cancer for Both Sexes, Aged Between 0-85 (in Million),Global, 2025-2050

North America Captured the Largest Market Share and is Expected to Retain its Dominance During the Forecast Period

North America holds the largest share in the pain management market, with the United States being the most significant contributor to its revenue. The factors such as increasing demand for long-term pain management from the geriatrics population, and developments in the field of pain management field boost the market growth in North America.

Additionally, as per the Centers for Disease Control and Prevention (CDC), chronic pain increased with age, and the highest was reported in patients aged 65 years and above in the United States. Moreover, the data published in October 2021 by World Health Organization (WHO) reported that the pace of population aging is much faster than in the past and by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. The high incidence of chronic pain among Americans and the growing geriatric population are expected to increase the demand for pain management devices and drugs over the forecast period. 

The COVID-19 outbreak is also expected to significantly impact the market's growth due to the increasing COVID-19 cases in the United States. According to the recommendations provided by the American Society of Regional Anesthesia and Pain Medicine (ASRA), chronic opioid therapy and the use of steroids in interventional pain procedures may induce immune suppression, which is very critical, as it minimizes the chances of fighting a viral infection. Hence, the COVID-19 pandemic is expected to negatively impact pain management procedures and the market in North America.

Overall, the United States pain management market is considered highly competitive, primarily due to the significant presence of pain specialist physicians, the increasing trend of product approvals from the United States Food and Drug Administration (FDA), and the robust infrastructure for providing pain management services to patients. For instance, in February 2020, Baudax Bio's meloxicam injection (Anjeso) received the United States Food and Drug Administration (FDA) approval to manage moderate to severe pain, alone or in combination with other nonsteroidal anti-inflammatory analgesics. Thus, the market is expected to grow significantly in North America over the forecast period.

Pain Management Market- Growth Rate By Region

Competitive Landscape

The pain management market is highly competitive and consists of several major players. The existing players in the pain management market employ strong competitive strategies, leading to intense competition. Some of the key players in the market are Abbott Laboratories, Johnson and Johnson, Baxter International Inc. (Avante Health Solutions), Becton, Dickinson and Company, and Boston Scientific Corporation, among others. 

Recent Developments

  • In July 2021, Venus Remedies Limited launched a consumer healthcare division that will offer various products for pain management.
  • In January 2021, Boston Scientific Corporation launched the WaveWriter Alpha, a portfolio of Spinal Cord Stimulator (SCS) systems that combine therapy options for personalized pain relief.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Demand for Long-term Pain Management from the Geriatric Population

      2. 4.2.2 Proven Efficacy of Pain Management Devices for the Treatment of Chronic Pain

      3. 4.2.3 Development of Novel Pain Management Devices and Techniques

    3. 4.3 Market Restraints

      1. 4.3.1 Lack of Awareness About the Availability and Use of Pain Management Devices

      2. 4.3.2 High Procedural and Purchase Cost of Pain Management Devices

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 Mode of Pain Management

      1. 5.1.1 Drugs

        1. Opioids

        2. Non-narcotic Analgesics

          1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

          2. Anesthetics

          3. Anticonvulsants

          4. Anti-depressants

          5. Other Non-narcotic Analgesics

      2. 5.1.2 Devices

        1. Neurostimulation Devices

          1. Transcutaneous Electrical Nerve Stimulation (TENS) Devices

          2. Brain and Spinal Cord Stimulation (SCS) Devices

        2. Analgesic Infusion Pumps

          1. Intrathecal Infusion Pumps

          2. External Infusion Pumps

    2. 5.2 Application

      1. 5.2.1 Neuropathic Pain

      2. 5.2.2 Cancer Pain

      3. 5.2.3 Facial Pain and Migraine

      4. 5.2.4 Musculoskeletal Pain

      5. 5.2.5 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Baxter International Inc. (Avante Health Solutions)

      3. 6.1.3 Becton, Dickinson and Company

      4. 6.1.4 Boston Scientific Corporation

      5. 6.1.5 Fresenius SE & Co. KGaA

      6. 6.1.6 Johnson & Johnson

      7. 6.1.7 Medtronic PLC

      8. 6.1.8 Novartis AG

      9. 6.1.9 Endo International plc

      10. 6.1.10 Pfizer Inc.

    2. *List Not Exhaustive

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Pain Management Market market is studied from 2022 - 2027.

The Global Pain Management Market is growing at a CAGR of 7.39% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, Becton, Dickinson and Company, Boston Scientific Corporation, Johnson and Johnson , Baxter International Inc. (Avante Health Solutions) are the major companies operating in Global Pain Management Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!